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Whether interleukin-17A (IL-17A) has pathogenic
and/or protective roles in the gut mucosa is contro-
versial and few studies have analyzed specific cell
populations for protective functions within the in-
flamed colonic tissue. Here we have provided evi-
dence for IL-17A-dependent regulation of the tight
junction protein occludin during epithelial injury that
limits excessive permeability and maintains barrier
integrity. Analysis of epithelial cells showed that in
the absence of signaling via the IL-17 receptor
adaptor protein Act-1, the protective effect of IL-
17Awas abrogated and inflammation was enhanced.
We have demonstrated that after acute intestinal
injury, IL-23R+ gd T cells in the colonic lamina propria
were the primary producers of early, gut-protective
IL-17A, and this production of IL-17A was IL-23
independent, leaving protective IL-17 intact in the
absence of IL-23. These results suggest that IL-17-
producing gd T cells are important for the mainte-
nance and protection of epithelial barriers in the
intestinal mucosa.
INTRODUCTION
Interleukin-17A (IL-17A) is the hallmark cytokine of the T helper
(Th17) cell subset of CD4+ T cells, which have been implicated
as the primary pathogenic population in a range of autoimmune
disorders (Langrish et al., 2005; Louten et al., 2009; Sallusto and
Lanzavecchia, 2009). IL-23 has been shown to promote the ter-
minal differentiation and expansion of Th17 effector cells and is
thought to orchestrate chronicity and severity in disease models
such as experimental autoimmune encephomyelitis (EAE) and
inflammatory bowel disease (IBD) (McGeachy et al., 2009; Park
et al., 2005; Yen et al., 2006). In Crohn’s disease (CD), SNPs in
the IL23R locus are associated with disease susceptibility (Duerr
et al., 2006), and patients with active CD present with increased
numbers of IL-23- and IL-17-expressing cells in the gut lamina
propria (Ho¨ltta¨ et al., 2008).However, increasing evidence suggests opposing effects of
the cytokines IL-23 and IL-17 in their contribution to intestinal
immunopathology. Murine models of innate (Buonocore et al.,
2010) and T-cell-driven (Ahern et al., 2010; Yen et al., 2006)
colitis demonstrate an inflammatory role for IL-23, and neutral-
izing IL-23 had a protective effect. The efficacy of neutralizing
IL-23 clinically has also shown some promise. Administration
of ustekinumab, a monoclonal antibody against the p40
shared subunit of IL-12 and IL-23, has shown positive re-
sponses in CD patients resistant to anti-tumor necrosis factor
alpha (TNF-a) treatment (Sandborn et al., 2012), and recent
data from a Phase 2a study for MEDI2070—a monoclonal
antibody against the p19 subunit of IL-23—has shown great
promise in treating TNF-a-therapy-resistant CD patients
(Sands et al., 2015, J. Crohn’s Colitis, abstract). 42.4% of
the patients on MEDI2070 experienced a clinical response
and reduced inflammatory scores compared to 10% in the
placebo group and treatment has not increased adverse
events, suggesting a more favorable benefit-risk profile
compared with the inhibition of both IL-12 and IL-23 through
sequestration of p40. In contrast to IL-23, various murine
models of colitis suggest a protective role for IL-17A. IL-17A
neutralization increases tissue damage in a dextran sodium
sulfate (DSS) model of IBD (Ogawa et al., 2004), and IL-17A-
or IL-17 receptor alpha (RA)-deficient T cells results in exacer-
bated colitis when transferred into RAG-1-deficient recipients
(O’Connor et al., 2009). Importantly, phase II clinical trials
with secukinumab, targeting IL-17A (Hueber et al., 2012), or
brodalumab, targeting IL-17RA (Targan et al., 2012), is ineffec-
tive in treating CD and results in either higher rates of adverse
events or worsening of CD, respectively. Although the data
clearly do not show any efficacy for neutralizing IL-17A or
IL-17RA in CD, the current understanding of the mechanism
of IL-17-mediated protective effects in both mouse and man
is lacking.
Given the suggested role of IL-17A in maintaining barrier
function of epithelial tissues (Kinugasa et al., 2000), we were
interested in addressing the protective effects of IL-17A on pre-
serving epithelial integrity in a DSS model of acute colonic
injury. We demonstrate that IL-17A promoted epithelial barrier
function by regulating the cellular localization of the tight junc-
tion protein occludin during DSS-mediated injury and protected
the mice from excessive gut permeability. In addition, our dataImmunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc. 727
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Figure 1. Il17–/– Mice Suffer Worse Epithelial
Injury and Enhanced Gut Permeability after
DSS Administration
(A) Weight loss of WT (squares) and Il17/ (triangles)
mice over time during DSS treatment, representative
data from three independent experiments, n = 5–7/
group, mean ± SEM.
(B) Colon length at day 7, combined data from three
experiments, mean ± SEM. *p < 0.05.
(C) Pathology scores of disease severity, means
indicated; ns, not significant. Combined data from
two experiments. H&E of colons reveal enhanced
edema and lymphocytic infiltrate in Il17/ colons
(arrows) after DSS, 203 magnification shown.
Scale bar in lower right panel represents 200 mm.
Combined data from two experiments.
(D) Detection of FITC-dextran in plasma showing
increased colon permeability in Il17/ over WT after
3 and 7 days of DSS, representative data from
three experiments, or combined data from three
experiments (day 7), means indicated, *p < 0.01.
All statistics generated by one-way ANOVA, with
Tukey’s multiple comparisons. See also Figure S1.show that IL-17A could mediate these protective effects by
signaling through the IL-17R adaptor protein Act-1 on epithelial
cells. We examined the production of IL-17 by multiple adap-
tive and innate cell populations after intestinal insult and found
that the initial source of tissue-protective IL-17A was primarily a
tissue-resident IL-23R+ gd T cell as opposed to a CD4+ ab
T cell or an innate lymphoid cell (ILC). The colonic gd T cells
did not require IL-23 signaling for the production of IL-17A,
and mice deficient for IL-23R were protected from the
increased barrier dysfunction after DSS treatment that is seen
in Il17/ mice. Importantly, neutralizing IL-23 dampened adap-
tive and innate cell activation while maintaining the production
of protective IL-17A during epithelial injury. Taken together,
these data provide a mechanism by which IL-17A-producing
gd T cells help protect the epithelial barrier against excessive
permeability after injury.728 Immunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc.RESULTS
Gut Epithelial Integrity Is
Compromised in theAbsence of IL-17
during Injury
In order to investigate the role of IL-17 in
disease progression after gut mucosal
injury, we administered DSS in the drink-
ing water to WT or Il17/ mice for
7 days. Mice were monitored and scored
according to weight loss, consistency of
stool, rectal bleeding, and colon length.
Overall weight loss and colon length were
comparable between WT and Il17/ mice
after 7 days of DSS treatment (Figures 1A
and 1B). Upon gross physical and histo-
logical examination, disease pathology
was comparable between Il17/ colons
and WT colons (Figure 1C). Although
both groups of mice exhibited epithelialdisruption and the presence of abscesses, the absence of
IL-17 was further characterized by enhanced bleeding into
the mucosal lumen as well as increased edema and cellular
infiltrate into the submucosal layer (Figures 1C). To further
characterize the damage to the epithelial layer, permeability
was quantified by orally administering FITC-dextran to mice
on day 3 and day 7 of DSS treatment and measuring the
amount present in the serum (Figure 1D). Although baseline
permeability in naive mice was similar between WT and Il17/
mice, the diffusion of FITC-dextran across the epithelium
after DSS treatment was significantly increased in colons
from Il17/ mice compared to those from WT mice at both
time points, suggesting that IL-17 deficiency reduced the
ability to maintain appropriate barrier function during DSS-
induced injury. To test whether the increased permeability
from Il17/ mice observed in DSS-induced injury was specific
to the model, we neutralized IL-17 in another mouse model of
colitis, the T cell transfer model. Anti-IL-17A antibodies did not
have any impact on weight loss throughout the course of the
disease as compared to controls, but the mice exhibited
increased FITC dextran permeabilization between 3 and
4 weeks after T cell transfer (Figures S1A and S1B). Neutraliza-
tion of IL-23R had a protective effect on the mice, clearly differ-
entiating IL-17 from IL-23 in colitis.
Sub-cellular Localization of the Tight Junction Protein
Occludin Is Altered in the Absence of IL-17A after
Intestinal Injury
An important component of maintaining intestinal barrier func-
tion is the formation and maintenance of tight junctions be-
tween epithelial cells. The tight junction complex, composed
of proteins including claudins, occludins, and zonula occlu-
dens 1 (ZO-1), is a critical structure in regulating intestinal
permeability and the epithelial paracellular pathway (Turner,
2009). Because IL-17A-deficient mice exhibited increased
intestinal permeability after gut injury, we hypothesized that
the epithelial tight junctions would be compromised in these
animals. Transcripts of Cldn7, Tjp1, and Ocln did not show
any differences between WT and Il17/ mice at baseline,
and whereas expression was modulated at day 3 after DSS,
IL-17 deficiency did not impact Tjp1 or Ocln (Figure 2A)
expression. Although transcripts of Ocln were similar between
WT and Il17/ colon tissue samples, altered intra-cellular
localization could explain the increase in permeability and
loss of barrier function. Tight junction disruption, including
internalization of occludin from the tight junction, has previ-
ously been demonstrated to contribute to increased intestinal
permeability (Clayburgh et al., 2005). Cross sectional images
of the colonic crypts of epithelial cells in naive mice showed
clear staining of occludin colocalized with F-actin on the apical
surface of the cell (Figures S2 and 2B). In contrast to naive or
control Ig-treated mice, in animals treated with anti-IL-17A, the
colon epithelial cells showed diffuse occludin staining that ap-
peared to extend into cytoplasm as well as a loss of co-local-
ization with F-actin. These results demonstrate that whereas
occludin message and protein expression do not seem to be
altered with IL-17A neutralization, its cellular localization and
ultimately tight junction function is impacted. To determine
whether IL-17 had a direct impact on occludin subcellular
localization, we turned to an in vitro system using the human
epithelial colon adenocarcinoma line, Caco-2. Caco-2 cells
express transcripts for IL17RA and IL17RC and respond to
recombinant IL-17 (Figure S3). TNF-a concentration is mark-
edly increased in mouse models of IBD as well as CD patients,
and TNF-a has been shown to disrupt tight junctions and
increase epithelial barrier permeability in Caco-2 cells (Ma
et al., 2004). Indeed, the addition of TNF-a into Caco-2 mono-
layers resulted in altered cellular localization for occludin,
leading to a disorganized staining pattern that extended into
the cytoplasm (Figure 2C). This TNF-a-mediated disruption
of occludin localization was dramatically decreased in the
presence of IL-17A. These results show that IL-17A can
directly regulate TNF-a-mediated disruption of tight junction
proteins in Caco-2 cells, and the data complement the effects
of neutralizing IL-17A observed in vivo.IL-17 Signals through an Act-1 Pathway in Epithelial
Cells to Maintain Barrier Integrity
Act-1 is an essential adaptor protein used by IL-17R to medi-
ate downstream cytokine signaling during an inflammatory
response (Qian et al., 2002, 2007). We would therefore hypoth-
esize that if IL-17 is maintaining epithelial integrity during DSS
colitis, we would expect that in the absence of Act1 signaling,
gut epithelium would exhibit enhanced pathology after treat-
ment with DSS. Act-1 was originally cloned as an NF-kB acti-
vator, but it has also been shown to negatively regulate B cell
function and humoral responses (Qian et al., 2004). In order to
test the specific contribution of IL-17R signaling on epithelial
cells, we utilized a mouse with a conditional deletion of Act1
driven by the expression of an epithelial-specific protein K18,
leaving Act-1 signaling intact in B cells. We induced DSS
colitis in control mice (K18creAct1fl/+) and epithelial-specific
Act-1-deficient mice (K18creAct1fl/) and examined changes
in the overall inflammatory response in the absence of IL-17-
mediated Act-1 signaling in epithelial cells (Figure 3A). The
expression of many inflammatory markers was upregulated in
the K18creAct1fl/ mice compared to control mice. These data
suggest that the Act-1 signaling pathway plays a role in IL-17-
dependent maintenance of epithelial barriers by regulating the
extent of inflammation during DSS-induced colitis. In addition,
we found that mice with the epithelial-specific deficiency in
Act-1 exhibited significantly increased gut permeability on day
3 after DSS-induced colitis, as measured by the presence of
FITC-dextran in the serum (Figure 3B). Together, these data pro-
vide one possible mechanism by which IL-17 signaling directly
on epithelial cells maintains mucosal integrity and functional
epithelial tight junctions.
Early IL-17 in the Intestinal Lamina Propria Is Produced
by a RAG- and RORgt-Dependent Population
In order to elucidate changes in proinflammatory cytokine
expression in the absence of IL-17, we analyzed colon samples
from WT and Il17/ mice 3 days after DSS administration by
RT-PCR. Expression of Ifng, Il22, Il23a, and Tnf was compara-
ble between the two groups (Figure S4). To determine the
specific contribution of cytokines from immune cells, colonic
lamina propria lymphocytes (cLPLs) were isolated and stimu-
lated overnight with either aCD3 or IL-23, and supernatants
were analyzed for cytokine protein. WT cells produced IL-
17A, IL-17F, IL-22, and IFN-g in response to both stimuli
(Figure 4A). Supernatants from cells deficient in IL-17A had
no inherent defect in overall cytokine production; all protein
concentrations were similar to WT mice, with the exception of
IL-17A. Taken together, these data support the conclusion
that the production of other cytokines by cLPLs is independent
of the ability to produce IL-17A and suggest that the increased
pathology in the colon of Il17/ mice is due primarily to the
absence of IL-17A.
We next sought to identify the primary source of IL-17 by
comparing WT and Rag1/ mice responses to DSS adminis-
tration. We found that compared to WT cLPL cultures, RAG1-
deficient cLPLs produced less IL-17A and IFN-g in response
to IL-23 or aCD3 stimulation (Figure 4B), suggesting that
both of these cytokines are mainly secreted by a RAG1-depen-
dent population. In contrast, IL-23, but not aCD3, inducedImmunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc. 729
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Figure 2. Dysregulation of Occludin Cellular
Localization in the Absence of IL-17A after
DSS-Induced Injury
(A) Colonic tissues were analyzed by RT-PCR for
Tjp1 and Ocln transcripts at day 3 and day 7 after
DSS treatment. Representative data from two ex-
periments. Error bars indicate SEM.
(B) C57BL/6 mice administered IgG or anti-IL-17A
(20 mg/kg) 2 days before DSS treatment. Immuno-
fluorescence images of occludin (green), F-actin
(red), and DNA (blue) of distal colon segments
3 days after DSS. The third column represents a
magnified image from the white box in the second
column. Scale bars represent 100 mm. Images
representative of three experiments. See also
Figure S2.
(C) Caco-2 cells plated on poly-L-lysine-coated
coverslips, treated with recombinant human TNF-a
(10 ng/ml) or TNF-a (10 ng/ml) + recombinant human
IL-17A (10 ng/ml) and cultured for 24 hr. Immuno-
fluorescence images of occludin (green) and
DNA (blue). The bottom row represents a magnified
image from the corresponding white box in the
first row. Scale bar represents 100 mm. Images
are representative of three experiments. See also
Figure S3.
730 Immunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc.
AB
Figure 3. Enhanced Inflammatory Signature in the Absence of IL-17-
Induced Act-1 Signaling in Epithelial Cells
(A) Epithelial cells from the distal colons of control or K18creAct1fl/ DSS-
treated mice were analyzed by RT-PCR. Transcripts of inflammatory genes
represented in a heatmap as fold change over the amounts in naivemice. Each
column represents an individual mouse; n = 5/group.
(B) Detection of FITC-dextran in plasma after 3 days of DSS. One of two ex-
periments is shown; *p value = 0.01; means indicated.IL-17F and IL-22 production in Rag1/ mice similar to the
concentrations observed in WT mice (Figure 4B). These data
indicate that the induction of IL-17F and IL-22 is RAG-1
independent.
We have previously shown that production of IL-17A by
CD4+ T cells is dependent on the transcription factor RORgt
(Ivanov et al., 2006). We sought to determine whether pro-
duction of IL-17A by CD3+ lymphocytes was dependent on
RORgt by treating Rorc/ mice with DSS for 3 days and
examining the cytokine production in culture supernatants
from isolated cLPLs. The absence of RORgt not only abro-
gated IL-17A and IL-17F production in response to aCD3 as
expected but also significantly reduced IL-22 production after
TCR ligation (Figure S5). Together these data provide evidence
that RORgt is required for the trans-activation of IL-23
signaling and optimal production of IL-17A, IL-17F, and IL-
22. Importantly, the results provided here implicate ‘‘innate’’
IL-17- and IL-22-secreting populations in the gut that require
RORgt for their effector function and contribute to gut protec-
tion after injury.gd T Cells Are the Primary Source of Early IL-17A
Production
Innate intestinal populations including ILC3s and tissue-resi-
dent gd T cells are early sources of both IL-17 and IL-22 (Martin
et al., 2009; Spits et al., 2013). In order to identify the specific
contribution of the various RORgt-expressing population to
IL-17 and IL-22 production, we isolated cLPLs from Rorc-GfpTG
mice after DSS administration and used surface marker ex-
pression to phenotype the different populations. Using GFP
expression to detect RORgt-expressing cells, we identified
three major RORgt+ populations in the colon after DSS treat-
ment: CD3+ gd T cells, CD4+ ab T cells, and CD3 ILC3s (Fig-
ure 5A). Intracellular staining for IL-17A and IL-22 revealed that
gd T cells were the major source of IL-17A in the lamina propria
after DSS-induced injury, with more than 30% of cells express-
ing the cytokine (Figures 5A and 5B) and very few IL-22-pro-
ducing gd T cells. In contrast to gd T cells, ILC3s were the
predominant source of IL-22 with approximately 50% of the
population staining positive for this cytokine, and very few cells
were positive for IL-17. CD4+ T cells only had a minor contribu-
tion to IL-17 and IL-22 at this early time point. These data sug-
gest that IL-17A and IL-22 are initially produced by distinct
innate cell populations in the gut lamina propria in response
to injury. In addition, we demonstrated that gd T cells are the
primary IL-17A-producing population. Thus, given their ability
to rapidly respond to proteins and inflammatory cytokines
(Cua and Tato, 2010), gd T cells, as opposed to ILC3s, are
important in maintaining epithelial integrity in our model through
the secretion of IL-17.
In general, distinct subsets of gd T cells exist and have unique
function and homing capabilities, including the ability to pro-
duce either IL-17A or IFN-g in response to a variety of stimuli
(Martin et al., 2009; Ribot et al., 2009). We next determined
the capacity of gd T cells in the mucosal lamina propria to
also produce IFN-g after injury induction. When naive cLPLs
were isolated and stimulated ex vivo with either PMA and iono-
mycin or IL-23, we found that whereas CD4+ T cells were the
largest IFN-g-producing population, it was gd T cells that again
were the major IL-17A producers (Figure 5C). In addition, after
DSS treatment, the gd T cells were still the main source of
IL-17A protein (Figures 5C and 5D). Although gd T cells were
the major producers of IL-17A in the colon lamina propria, a mi-
nor population of CD4+ T cells was also positive for this cytokine
ex vivo, particularly after PMA and ionomycin stimulation. To
test the specific contribution of gd T cells in barrier function dur-
ing acute DSS injury, we utilized Tcrd/ mice for our studies.
We did not find any gd T cells in the colon lamina propria of
Tcrd/mice (Figure 5E) and did not observe any compensatory
increase in the frequency of IL-17-producing CD4+ T cells or
CD4CD8 double-negative T cells (Figure 5F). Consistent
with our hypothesis of a protective role for gd T cells during
DSS injury, Tcrd/ mice exhibited increased FITC dextran
permeability (Figure 5G). Finally, we did not observe a protective
role for CD4+ T cells, as their depletion in vivo did not impact
gut permeability (Figure 5G). These data provide evidence that
gd T cell populations in the gut lamina propria are readily able
to produce IL-17A protein upon activation and that these innate
T lymphocytes are the early source of tissue-protective IL-17A
during gut epithelial injury.Immunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc. 731
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Figure 4. Cytokine Production by Colonic Lamina Propria Cells after DSS-Induced Injury
Colonic LPLs restimulated with media, IL-23, or aCD3 overnight and supernatant analyzed by ELISA or luminex to determine concentrations of IL-17A, IL-17F,
IFN-g, and IL-22.
(A) Cytokine protein concentrations detected in supernatants of cLPLs isolated from either WT (open bars) and Il17/ (closed bars) mice, *p < 0.016; **p = 0.007.
Data are representative of two independent experiments. Error bars indicate SEM. See also Figure S4.
(B) WT and Rag/ mice: IL-17A, *p = 0.0001, **p < 0.005; IFN-g, *p < 0.048, **p < 0.006. Data are representative of two independent experiments. Error bars
indicate SEM. See also Figure S5.IL-17 Production by gd T Cells Is Independent of IL-23
Signaling
Having shown that the tissue-resident RORgt+ gd T cells are
potent producers of IL-17 in response to IL-23, we wanted to
determine whether IL-23 signaling was required for the early
IL-17 production during injury. To do this, we made use of the
Il23r-Gfp homozygous genetically targeted mice that allowed
us to compare IL-17 production in the presence or absence of
IL-23R expression. GFP+ cells isolated from Il23r-Gfp+/ and
Il23r-Gfp+/+ littermates after DSS administration were restimu-
lated ex vivo and compared for IL-17 production. Significantly
less IL-17 production was observed in the GFP+ cLPLs from
Il23r-Gfp+/+ than from Il23r-Gfp+/ mice (Figure 6A), indicating
that IL-23 does contribute to a portion of the overall IL-17 pro-
duction early after injury. Although there was a significant reduc-
tion in the number of gd T cells in the colon in the absence of
IL-23R signaling, the proportion of IL-17+ cells was comparable
between strains (Figure 6B). In contrast, no difference was found
in either the proportion of CD4+ cells present in the colon or in the
percentage of IFN-g+ cells whether or not IL-23R was present
(Figures S6A and S6B).We hypothesized that the IL-23-indepen-
dent gd T cells would still be able to produce protective IL-17 and
confer barrier function in the absence of IL-23R signaling during
DSS injury. Although both WT and Il23r/ mice rapidly lost
weight (Figure 6C) and exhibited epithelial disruption and the
presence of abscesses, Il23r/mice did not exhibit a decrease
in barrier function after administration of DSS at both day 3 and732 Immunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc.day 7 (Figure 6D). Serum FITC dextran concentration was lower
in Il23r/ mice than in WT animals at day 3. In support of the
maintenance of barrier function, Il23r/ mouse colon epithelial
cells did not exhibit cytoplasmic localization of occludin but
had a staining pattern similar to WT epithelial cells in the crypts
(Figure 6E). These data suggest that the early dysregulation
of barrier function during DSS is dependent on the absence of
IL-17, but not IL-23. Barrier function in IL-23R-deficient mice
was comparable to WT mice, if not enhanced at early time
points, and we show that in contrast to neutralizing IL-17A alone,
targeting IL-23 preserves protective IL-17A produced by IL-23R-
independent colonic gd T cells, which promotes maintenance
of epithelial barrier function.
DISCUSSION
IL-17 promotes the expression of proteins in mucosal tissues
that are involved with barrier function during an infection with
pathogenic organisms (Kao et al., 2004; Kinugasa et al., 2000;
Ogawa et al., 2004). Some of these proteins, such as cellular
tight-junction protein, ZO-1, become de-localized early after
DSS treatment and this is thought to be a marker of epithelial
injury (Poritz et al., 2007). In addition to these studies, our data
have shown that the absence of IL-17A results in increased
epithelial injury and compromised barrier function after DSS
treatment. We have shown that IL-17A regulated the cellular
localization of the tight junction protein occludin within the crypts
of colon epithelial cells during injury, and IL-17R-dependent acti-
vation of Act-1 in epithelial cells prevented excess inflammation
after DSS. Mice with a conditional deletion of Act-1 in epithelial
cells showed an increase in gut permeability after DSS, reinforc-
ing the protective role for IL-17 in barrier function. TNF-a-medi-
ated barrier disruption in Caco-2 monolayers was reversed with
the addition of recombinant IL-17A, suggesting a direct role for
IL-17 and IL-17R signaling on epithelial cells in the regulation
of occludin. IL-17 is a key regulator of antimicrobial responses
at mucosal surfaces, and in cooperation with IL-22 induces the
expression of antimicrobial proteins including beta defensins,
calgranulin, and lipocalin (Kolls et al., 2008). IL-17 contributes
to defense against the gram-negative pathogens Klebsiella
pneumonia and Citrobacter rodentium as well as having an
essential role in mucocutaneous immunity against Candida
albicans (Puel et al., 2011). Given the role of IL-17 in antimicrobial
responses, there is the possibility of an altered microbiota in IL-
17-deficient mice contributing to increased gut permeability in
the DSS injury model. Although these concepts need to be
further investigated, the data presented here demonstrate one
potential mechanism by which IL-17A signaling through Act-1
supports barrier function: by maintaining occludin localization
at tight junctions during DSS injury.
IL-17 has generally been classified as a pathogenic cytokine in
a variety of inflammatory diseases. Although IL-17 and IL-17R
signaling was shown to contribute to pathogenicity in a DSS
model of colitis (Qian et al., 2007), it is important to note that
the data we present suggest a protective role for IL-17A during
an acute model of gut injury. In fact, in the clinical trial with
sekukinumab for Crohn’s disease (Hueber et al., 2012), it was
specifically the patients with elevated CRP concentrations that
experienced a treatment-associated worsening of disease, sug-
gesting an important protective role for IL-17 during an acute and
active inflammatory response, consistent with our findings in the
acute DSS injury model. Chronic and long-term production of
IL-17 mediates inflammatory effects and neutrophil recruitment
into the gut, and a more subtle, low-dose chronic DSS injury
model could allow us to address how long-term increases in
gut permeability and IL-17 can influence IBD disease course.
We have identified an important function of IL-17 modulating
TNF-a-driven disruptions in epithelial tight junction proteins,
and whether this applies in the clinic needs to be tested.
Although the protective role of IL-17A has been discussed in
the literature, few studies have analyzed specific IL-17A-produc-
ing cell populations for their functional significance within the in-
flamed tissue. Our results involving the gut mucosa concur with
previously published work with lung and skin models in which
subsets of gd T cells are important for barrier protection
(D’Souza et al., 1997; Jameson et al., 2002; Nakasone et al.,
2007). In addition to their protective role in the lung and skin,
we have provided evidence in this study that gd T-cell-derived
IL-17A in the colonic lamina propria also provided protection
within the colon during DSS injury. We have shown that colonic
gd T cells were the primary producers of gut-protective IL-17A
and were dependent on RORgt but not IL-23 for their function.
RORgt+ T helper 17 (Th17) cells are also characterized by the
production of IL-17. However, in our animal housing conditions,
we found that CD4+ Th17 cells made up a very minor subset of
IL-17-producing cells at 3 days after DSS treatment. In contrastto the subset of gut gdT cells that produced constitutive IL-17,
CD4+ T cells required PMA and ionomycin stimulation ex vivo
to detect IL-17, which might not be representative of their pro-
duction in vivo. Further confirming the minor contribution of
CD4+ T-cell-derived IL-17, depleting CD4+ T cells did not have
an impact on FITC dextran permeability, whereas Tcrd/ mice
showed a clear increase in gut leakiness. The Tcrd/ study
combined with the CD4+ T cell depletion experiment demon-
strate the critical function of IL-17-producing gd T cells in pro-
tecting barrier surfaces. Our analysis of colonic tissue after early
injury confirms the existence of a protective role for gd T-cell-
derived IL-17A in the colon that works to limit permeability of
the epithelial barrier in order to reduce common complications
of mucosal injury, such as excessive edema and anemia.
Our data show that IL-22 production, often associated with
IL-17-secreting cells, is independent of the ability to produce
IL-17A (Liang et al., 2006; Veldhoen et al., 2008). Colonic LPLs
isolated from Il17/ mice and re-stimulated with IL-23 after
injury led to normal IL-22 production despite the absence of
IL-17. It is tempting to speculate whether the balance between
IL-17 and IL-22 can mediate their protective or pathogenic
effects on the epithelium. This interplay between IL-17 and
IL-22 has previously been demonstrated in lung epithelial cells
(Sonnenberg et al., 2010). However, further work will need to
be done to determine whether the pathogenic or protective ef-
fect of IL-22 in the gut epithelium can be regulated depending
on the presence or absence of IL-17A. Although IL-22 is gener-
ally thought to be protective at mucosal surfaces, in certain
circumstances it is known to promote inflammation. IL-22 has
been shown to stimulate epithelial cell production of chemokines
that recruit inflammatory myeloid cells including CXCL1, CXCL2,
and CXCL5 (Eken et al., 2013), as well as the proinflammatory
cytokine IL-18 (Mun˜oz et al., 2015). Thus, uncontrolled produc-
tion of IL-22 in concert with other cytokines might contribute to
inflammation. We have demonstrated that neutralizing IL-23R
signaling in a T cell transfer model of colitis was efficacious in
limiting disease, even when treated at later time points, whereas
neutralizing IL-17 recapitulated many of the similar phenotypes
we observed in the DSS model of colitis, including increased
gut permeability and weight loss. In contrast to IL-23, these
two different mouse models of gut damage and human clinical
trials consistently demonstrate a protective role for IL-17.
Although IL-23 is an important cytokine for driving IL-17
responses, we have shown that the early protective IL-17A is in-
dependent of IL-23 and that the absence of IL-23 signaling does
not lead to excessive barrier dysfunction during DSS injury.
These findings provide a potential explanation of the dramatic
differences between neutralizing IL-23 and IL-17A in DSS injury
and epithelial permeability. Although there was a significant
decrease in the frequency of IL-17-producing cells in IL-23R-
deficient animals, IL-23-independent production of protective
IL-17 was still intact in the gd population found in the colonic
tissue. We propose that neutralizing IL-23 minimizes tissue
inflammation and T cell and myeloid cell activation while leaving
the protective function of IL-17 from gd T cells intact. This early
IL-17 production by gd T cells in our model establishes this pop-
ulation as a major player in limiting inflammation-induced dam-
age in gut epithelium after an injury through an Act1-dependent
mechanism of protection. It is notable that gd T intra-epithelialImmunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc. 733
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Figure 5. Different Subsets of cLPLs Produce either IL-17 or IL-22 after Restimulation
(A) Dot plots of the three major RORgt-expressing populations from cLPLs isolated after 3 days of DSS. Intracellular cytokine analysis of cLPLs
showing IL-17 versus IL-22 production for each population after 3 hr of restimulation in vitro. Representative dot plots from three independent experiments
are shown.
(B) Percentage of RORgt-GFP+ cells expressing either IL-17 or IL-22 by population, combined data from two experiments are shown, means ± SD.
(C) Detection of intracellular IL-17 (x axis) and IFN-g (y axis) in cLPLs from either naive or day 3-DSS-treatedmice after 3–4 hr restimulation ex vivo. Representative
zebra plots from two independent experiments show either a CD4+ T cell gate (top two rows) or a gd+ T cell gate (bottom two rows).
(D) Bar graph showing percentage of either CD4+ or gd T cells fromDSS-treated mice that are positive for IFN-g (top) and IL-17 (bottom), combined data from two
experiments, with means ± SEM (*p < 0.0001; **p < 0.04). Two-tailed, Student’s t test performed.
(E) Colon LPLs from Tcrd+/ and Tcrd/ mice gated on live, CD3+Thy1+ cells. Representative of two independent experiments.
(legend continued on next page)
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Figure 6. IL-23R-Deficient Mice Do Not
Exhibit Increased Gut Permeability after
DSS Treatment
(A) IL-23R expression in different lamina propria
lymphocyte populations as determined by Il23r-
Gfp reporter using Il23r-Gfp+/ mice, combined
data from two experiments; means indicated.
(B) IL-17 production is decreased overall in the
absence of IL-23R signaling as shown by com-
parison of Il23r-Gfp+/ (GFP+/) (IL-23R present)
and Il23r-Gfp+/+ (GFP+/+) (IL-23R absent) mice for
all GFP+ cLPLs (left) or gd T cells only (right). Data
from two experiments; means indicated. See also
Figure S6.
(C)Weight loss ofWT (squares) and Il23r/ (circles)
mice over time during DSS treatment, representa-
tive data from three independent experiments,
n = 5–7/group, mean ± SEM.
(D) Detection of FITC-dextran in serum after 3 and
7 days of DSS. Representative data from two ex-
periments, or combined data from two experiments
(day 7), means indicated, *p < 0.01. All statistics
generated by one-way ANOVA, with Tukey’s
multiple comparisons.
(E) Immunofluorescence images of occludin
(green), f-actin (red), and DNA (blue) of distal colon
segments from WT or Il23r/ mice 3 days after
DSS. The third column represents a magnified
image from the white box in the second column.
Representative of three independent experiments.lymphocytes (IELs) can also stimulate mucosal healing after
6 days of DSS treatment and recruit macrophages to injured
areas to prevent commensal penetration after damage (Ismail
et al., 2009; Pull et al., 2005). Therefore, it is clear from these
studies that there exist multiple mechanisms by which gd
T cells and their secretion of IL-17A are important for the mainte-
nance, protection, and repair of epithelial barriers in intestinal
mucosa.
Recently, a clinical study tested the efficacy of an anti-IL-17A
monoclonal antibody in treatment of Crohn’s disease. Blockade
of IL-17A in these patients exacerbated their disease and
was characterized by an increase in inflammatory markers over(F) Colon LPLs as in (E), stimulated with PMA and ionomycin and gated on the populations indicated. Representative of two independent experiments. Error bars
indicate SEM.
(G) Detection of serum FITC dextran after 3 days of DSS. Representative of two independent experiments. Error bars indicate SEM. **p < 0.004. Two-tailed
unpaired t test.
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more, for a subset of patients taking the
drug, 44% developed additional infec-
tions, whereas none in the placebo group
had an adverse event related to infection
(Hueber et al., 2012). Similar results were
obtained in a separate study targeting
IL-17RA (Targan et al., 2012), further con-
firming the deleterious effects of neutral-
izing IL-17A or IL-17 signaling for the
treatment of CD. Although elimination of
IL-17A has been efficacious in other in-
flammatory disorders such as psoriasis
its failure in the treatment of CD is yet another cautionary tale
of the pleiotropic effects of cytokines used as therapeutics
(Shen and Durum, 2010). These clinical studies are a strong
endorsement of the protective effects of IL-17A in human intes-
tinal mucosa and provide further support for the data presented
within this paper.EXPERIMENTAL PROCEDURES
Mice
Il17/, Rorc/, Rorc(gt)-GfpTG, Il23r-Gfp, and Tcrd/mice were derived as
previously described and bred and housed within micro isolator caging units,
at MRL (Awasthi et al., 2009; Ivanov et al., 2006; Lochner et al., 2008; Nakae
et al., 2002). Rag1/ and WT C57BL/6 or littermate controls were used as
age- and sex-matched controls where indicated (Jackson Laboratories).
K18creAct1fl/ mice were provided by Xiaoxia Li and have been described
previously (Qian et al., 2007; Swaidani et al., 2009) All animal procedures
were approved by the Institutional Animal Care and Use Committee of Merck
Research Laboratories in accordance with guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care.
DSS and FITC-Dextran Administration
Mice were given 3.5% DSS in drinking water for 3 days before lamina propria
cells were isolated from the colons for in vitro culture or a 1 cm length of the
distal colon was snap frozen for taqman analysis. Alternatively, DSS drinking
water was administered for 7 days and mice were monitored for weight loss
and signs of disease. RNA isolation and real-time PCR was performed as pre-
viously described (Fehniger et al., 1999; McGeachy et al., 2009). Mice were
gavaged with FITC-Dextran (4 kDa, Sigma Aldrich) as previously described
(Dawson et al., 2009) 3 hr prior to fluorometric analysis of FITC fluorescence
in plasma.
T-Cell-Driven Colitis
Spleen cells from BL/6 mice were processed through 100 mm nylon filters and
purified for CD4 using magnetic bead separation (Myltenyi). CD3+CD4+
CD25CD45RBhi T cells were sorted with FACS Aria (BD). The cells
(3 3 105) were injected intravenously, and mice were monitored and weighed
for 5 weeks after injection. At the study endpoint, mice were sacrificed, and
serum and intestines were collected for analysis. Anti-IL-23R (Merck, mouse
IgG1) and anti-IL-17A (Merck, mouse IgG1) and isotype control (Merck, mouse
IgG1) were administered s.c. at day 14 after transfer at a dose of 50 mpk, and
once weekly until 42 days after transfer.
Histology
Dissected colons were fixed in 10%NBF before embedding in paraffin. Hema-
toxylin and eosin staining was performed on sections of tissue for grading of
pathology. All images were acquired with the Zeiss Mirax Midi scanner with
a 203 objective.
Immunofluorescence Microscopy
Distal colons were flushed with PBS, embedded in Tissue-Tek O.C.T. com-
pound (SAKURA Finetechnical Company) in cryomolds, and snap frozen in
liquid nitrogen for cryosectioning. Cryosections were prepared on a Leica
Cryostat (Leica Microsystems) at 21C in 5 mm thickness. Sections were
mounted on glass slides and fixed in 100% ethanol at 4C for 30 min followed
by 3 min of 20C acetone fixation at room temperature. The slides were
washed in PBS and blocked in FBS and rabbit serum. The tissue sections
were stained with a monoclonal occludin antibody OC-3F10 (Life Technolo-
gies) at 4C overnight. After washing in PBS, the sections were stained with
a rabbit anti-mouse IgG Alexa Fluor 488 conjugated secondary antibody
(Life Technologies) and Alexa Fluor 546 Phalloidin (Life Technologies) for
60 min at room temperature. The tissue sections were treated with ProLong
Mountant with DAPI (Life Technologies) and covered with a coverslip. Fluores-
cence was visualized on the EVOS FL Cell Imaging System (Life Technologies)
at 403 magnification.
Colonic Lamina Propria Cell Isolation
Colons were removed from naive and DSS-treated mice and epithelial cells
were stripped by incubating in a 37C water bath in cell dissociation solution
made with HBSS (BioWhittaker), 5 mM EDTA (Invitrogen), and 10 mM HEPES
(Life Technologies). Supernatant with IEL and epithelial cells was discarded
and colonic tissue was then incubated in a digestion cocktail containing
HBSS, 10% FCS (Hyclone Laboratories), 1 mg/ml collagenase type IV,
0.5 mg/ml DNaseI, and 0.5 mg/ml dispase (all from Sigma-Aldrich) in a 37C
water bath. Digested tissue was processed through a 70 mm filter and washed
before lymphocytes were separated using a percoll gradient (GEHealthcare)
and resuspended in complete RPMI (Mediatech) supplemented with 10%
FCS (Hyclone), 1%HEPES, 50 mM2-mercaptoethanol (Invitrogen), 1%sodium
pyruvate, and penicillin and streptomycin (both from Mediatech).736 Immunity 43, 727–738, October 20, 2015 ª2015 Elsevier Inc.Cell Culture
Colonic lamina propria cells were isolated as above and put into single-cell
suspensions at 1 or 2 3 106 cells/ml. Cells were plated for a final volume
of 200 ml and restimulated with media alone, 40 ng/ml of IL-23 (DNAX),
10 ng/ml of IL-12 (DNAX), or 4 mg/ml of aCD3 (BioXcell) for 20 hr or with
PMA and ionomycin for 3 hr. Caco-2 [Caco2] (ATCC HTB-37) were cultured
in Eagle’s Minimum Essential Medium in 20% FBS according to ATCC
instructions.
Flow Cytometry
For intracellular cytokine staining, cells were stimulated with 50 ng/ml PMA
and 500 ng/ml ionomycin (both Sigma-Aldrich) in the presence of Golgi-plug
(BD Biosciences) for 4 hr in complete medium. Surface staining was then
performed in the presence of Fc-blocking antibodies (2.4G2, BD) and using
aCD3 (500A2, BD), aCD4 (RMU-5, BD), aTCRb (H57-597, BD), a-gdTCR
(UC7-13D5, eBioscience; or GL3, BD), and a-NKp46 (29A1.4, eBioscience).
Cells were then fixed and permeabilized with cytofix-cytoperm kit (BD) as
directed before intracellular staining using antibodies against IFN-g, IL-22,
and IL-17A (all from BD). All samples were collected with Canto II (BD) and
data were analyzed with FlowJo software (Tree Star).
RNA Isolation
For gene expression analysis, RNA was isolated by homogenizing colons into
RNA STAT-60 (Tel-Test) using a polytron homogenizer, then extracting total
RNA according to themanufacturer’s instructions. After isopropanol precipita-
tion, total RNA was re-extracted with phenol:chloroform:isoamyl alcohol
(25:24:1) (Sigma-Aldrich) using phase-lock light tubes (5 Prime, Thermo Fisher
Scientific). For DSS-treated samples, total RNA was isolated using RNeasy
Midi method (QIAGEN), where tissue was first homogenized into RLT Buffer
plus beta-Mercaptoethanol using a polytron homogenizer, and according to
manufacturer’s instructions. Total RNA was then re-cleaned over Rneasy
Mini columns (QIAGEN) according to manufacturer’s protocol.
Real-Time Quantitative PCR
DNase-treated total RNA was reverse-transcribed with QuantiTect Reverse
Transcription (QIAGEN) according to manufacturer’s instructions. Primers
were designed with Primer Express (Applied Biosystems, Life Technologies)
or obtained commercially from Applied Biosystems. Gene-specific preamplifi-
cation was done on 10 ng cDNA per Fluidigm Biomark manufacturer’s instruc-
tions (Fluidigm). Real-time quantitative PCR was then done on the Fluidigm
Biomark using one of two different chemistries. For the first chemistry,
two gene-specific unlabelled primers were utilized at 400 nM with Taqman
Gene Expression Master Mix plus EvaGreen. For the second chemistry, two
unlabelled primers at 900 nM each were used with 250 nM of FAM-labeled
probe (Applied Biosystems, Life Technologies) with Taqman Universal PCR
Master Mix with UNG. Samples and primers were run on 96.96 Array(s)
per manufacturer’s instructions (Fluidigm). The absence of genomic DNA
contamination was confirmed with primers that recognize genomic region of
the CD4 promoter. Ubiquitin transcripts was measured in a separate reaction
and used to normalize the data by the D-D Ct method. (Using the mean cycle
threshold value for ubiquitin and the gene of interest for each sample, the
Equation 1.8 ^ (Ct ubiquitin minus Ct gene of interest)3 104 was used to obtain
the normalized values.)
Luminex
Plasma cytokine concentrations were measured with Luminex system
(Millipore Corporation). Plasma samples were collected and spun at
6,000 rpm for 15 min at 4C and was collected and stored at 80C analysis.
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